Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials

English version České info

In a Perspective, Francisco Beca and Andrew Beck discuss Charles Swanton and colleagues' accompanying Research Article on somatic mutations in patients with inflammatory breast cancer treated in a Phase II clinical trial.

Vyšlo v časopise: Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials. PLoS Med 13(12): e32767. doi:10.1371/journal.pmed.1002177
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002177

Souhrn

Zdroje

1. Lemonick MD, Park A. New Hope For Cancer. Time Magazine. 2001 May. http://content.time.com/time/covers/0,16641,20010528,00.html

2. National Human Genome Research Institute. The Cost of Sequencing a Human Genome. National Human Genome Research Institute website. [cited 2016 Jan 1]. https://www.genome.gov/sequencingcosts/

3. Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov;1(8):1154–61. http://www.ncbi.nlm.nih.gov/pubmed/26204261 doi: 10.1001/jamaoncol.2015.2286 26204261

4. Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat. 2015 Nov;154(1):155–62. http://www.ncbi.nlm.nih.gov/pubmed/26458824 doi: 10.1007/s10549-015-3592-z 26458824

5. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, et al. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb;125(3):785–95. http://www.ncbi.nlm.nih.gov/pubmed/21153052 doi: 10.1007/s10549-010-1280-6 21153052

6. Parker JS, Perou CM. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest? Cancer Cell. 2015 Aug 10;28(2):149–50. http://www.ncbi.nlm.nih.gov/pubmed/26267531 doi: 10.1016/j.ccell.2015.07.011 26267531

7. Beca F, Polyak K. Intratumor Heterogeneity in Breast Cancer. Adv Exp Med Biol. 2016;882:169–89. http://www.ncbi.nlm.nih.gov/pubmed/26987535 doi: 10.1007/978-3-319-22909-6_7 26987535

8. Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, et al. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med. 2016;13(12):e1002136. doi: 10.1371/journal.pmed.1002136

9. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015 Oct;12(10):573–83. http://www.ncbi.nlm.nih.gov/pubmed/26122181 doi: 10.1038/nrclinonc.2015.117 26122181